INTRODUCTION
Leukotrienes (LTs) play an important role in normal inflammatory processes. They are also intimately involved in allergic asthma, atopic dermatitis, allergic rhinitis, arthritis, atherosclerosis and ischemia, tumorigenesis, and septic shock [1] [2] [3] [4] [5] [6] [7] . LTs COX-1 and COX-2 could be accounted for due to compartmentalization within the cell. Both enzymes, however, are associated with the endoplasmic reticulum and nuclear membranes in equal proportions [13] . The cyclooxygenase activity of COX-2 requires approximately 10-fold less hydroperoxide for activation than that of COX-1, and metabolizes AA with a greater turnover rate [12] . It has also been shown that both COX-1 and COX-2 produce maintenance levels of PGI 2 , a vasodilator, from human endothelial cells [14] . PGI 2 is, however, produced at a faster rate by COX-2 with a threefold lower K m and 2.5-fold faster initial rate of velocity compared to COX-1 [15] .
In addition, each isozyme appears to be coupled to specific synthases and/or isomerases for the final conversion of the Selective COX-2 inhibitors were conceived and designed to preserve PG production in the stomach and, thus, reduce the incidence of upper GI damage [16, 17] . Six-month, well-controlled trials of celecoxib against traditional NSAIDs have shown this selective COX-2 inhibitor to be GI sparing [17, 18] . In an analysis by the US Food and Drug Administration (FDA), however, follow-up of subjects in the Celecoxib Longterm Arthritis Safety Study (CLASS) trial for an additional 6 months after the trial ended showed that when total ulcer complications were considered, according to the pre-specified criteria in the trial protocol, there was no appreciable difference in cumulative percentage between celecoxib and traditional NSAIDs [19, 20] . Until longer, well-controlled, or phase 4 studies are performed comparing celecoxib to traditional NSAIDs, there will be no definitive answer on this subject. Part of the reason for long-term ulcer complications with selective COX-2 NSAIDs may be that both COX-1 and [26, 27] . In animal models of MI, the concentrations of PGs and PCs were reduced when rats and mice were administered a selective COX-2 inhibitor compared with a placebo [28] .
A meta-analysis of more than 4400 patients taking celecoxib for at least 6 weeks showed that there was an increase in MI over placebo, whereas there was no difference in composite analysis of CV deaths and strokes to placebo [29] .
In addition, the same authors showed a PGs are potent renal vasodilators and, together with PCs, are required for proper renal perfusion and regulation of salt balance [35] . In the kidney, COX-2 is produced constitutively and upregulated in the presence of salt deprivation [36] . In the presence of reduced circulatory volume, increased production of vasoconstrictive compounds, such as Txs, supports blood flow by increasing blood pressure. In hypertensive individuals, selective COX-2 inhibitors were found to further increase systolic pressure [37, 38] ; thus, contributing to the increased incidence of acute CV events [39] .
Chronic NSAID users (n=882) with hypertension 
NSAID-ASSOCIATED, LT-MEDIATED ORGAN TOXICITY

Pulmonary
In patients with aspirin intolerance, nasal secretions contain increased levels of LTC 4 and LTD 4 histamine, and FLAP [55, 56] . The incidence of aspirin-intolerant syndrome is about 10% of the US population, with most NSAIDs showing some level of cross-reactivity [57, 58] . COX-2 inhibitors also cross-react with aspirin with a much lower incidence and the order of crossreactivity appears to vary inversely with the [90] .
In the VIGOR trial, rofecoxib showed a fourfold increase in CV-related events compared with naproxen [16] . Additionally, a retrospective study of over 54,000 patients in two different health plans showed a threefold increase in heart attack among elderly adults in the first 90 days of rofecoxib therapy of 25 mg or greater per day [91] .
Similarly, in a retrospective cohort study of 610,001 persons in a Medicaid population, acute MI, stroke, and death from coronary heart disease for patients taking celecoxib, rofecoxib, valdecoxib, ibuprofen, naproxen, diclofenac, and indomethacin were studied [92] . An A variety of cardiopulmonary complications highlight the interplay between the COX enzymes and the 5-LOX pathway [21, 98] .
Afferent vessel response in ischemic reperfusion
is abolished by indomethacin in rats [99] .
A specific 5-LOX inhibitor reverses this effect, presumably by suppressing LT production. 
Renal
Oxidative status and inflammation contribute to kidney disease, particularly during renal failure and hemodialysis [107] . Low polyunsaturated fatty acid intake correlates with the development of renal disease [108] . COX-1 and COX-2, as well as metabolites generated from polyunsaturated fatty acids by these enzymes, are important for renal function. In the kidney, COX-2 is produced constitutively [109] . Both PGs and PCs are required for proper renal perfusion and as key regulators of salt balance [35] . PGs, like PCs, are strong renal vasodilators, which maintain urine production by regulating renal blood flow.
It has been found that macrophages present in the glomeruli synthesize LTB 4 when exposed to calcium ionophore, suggesting that the 5-LOX pathway is part of the normal regulatory capacity within the kidneys [110] . 5-LOX and FLAP are expressed at higher levels in humans with glomerulonephritis [111] . [115, 116] . Zileuton, a 5-LOX inhibitor, reduces the inflammatory effects of LTB 4 in wild-type animals in this model [117] .
In human clinical trials, although there was a lower incidence of hypertension with licofelone, there was no statistical difference between naproxen and licofelone in edema [118] .
Tepoxalin did not affect renal function in canines [119, 120] . Flavocoxid showed no statistically significant effect on markers of renal function in three different animal species [121] [122] [123] or in humans [82, 121, 124] . In a long-term, randomized, double-blind study there was a nonstatistically significant trend toward reduction in serum creatinine in the flavocoxid group compared with a similar trend toward an increase in creatinine in the naproxen group [81] .
Further long-term studies of dual COX/5-LOX inhibitors are required to clarify their overall renal safety.
Musculoskeletal
The etiology of OA is complex and often initiated by injury or trauma. During subsequent development of the disease, metabolic and inflammatory factors contribute to cellular and cartilage degradation leading to the release of phospholipids from damaged cells, which are then converted by PLA 2 into AA [125] . Other factors, such as a dietary imbalance between omega-6 and omega-3 fatty acid consumption, have also been implicated as a potential contributing factor to OA [126, 127] . Treatment with NSAIDs also has the potential to aggravate cartilage damage by increasing intra-articular LT levels.
A greater induction of FLAP in cultured subchondral osteoblasts from patients with more severe OA was seen than from patients with moderate arthritis [128, 129] RA, a true inflammatory arthritis, is also treated with NSAIDs along with disease modifying agents, biologics, and other therapies.
It has long been known that RA patients have elevated LT both systemically, excreted in urine, and in synovial fluid [143] [144] [145] .
In RA, synovial fluid contains dramatically elevated numbers of leukocytes comprised predominantly of neutrophils [146] .
Although the involvement of LT in RA is not completely understood, LT-deficient mice have been shown to be remarkably resistant to induction of inflammatory joint damage [147] .
Significant elevations of LTB 4 and LTC 4 from neutrophils are also present in animal models that mimic RA, suggesting that the 5-LOX pathway is significantly involved in generating inflammatory arthritis [148, 149] . factors [152] . NSAIDs may also be etiologically associated with atopic dermatitis, especially in canines [153] . As with urticarial reactions [154] , reduction of LT activity is essential for control of this condition.
The lower digestive tract is particularly sensitive to the effects of antiinflammatory drugs, both from de novo-induced damage and from exacerbation of pre-existing inflammatory bowel diseases (IBD) [155] . IBDs are, in part, mediated by LTs [156] . NSAIDs aggravate these diseases by increasing production of ROS and LTs [157] .
Although specific 5-LOX inhibitors, such as zileuton, have been used to treat conditions related to IBD [158] , licofelone and tepoxalin have not been tested in these clinical settings.
Flavonoids, like those in flavocoxid, reduce inflammation related to lower bowel diseases [159] . In an animal model of acute pancreatitis, flavocoxid reduces 5-LOX levels, blunts the induction of LTB 4 , reduces enzyme elevations, and preserves pancreatic histology [160] .
COX/5-LOX "DUAL INHIBITORS" AND THEIR MECHANISMS OF ACTION
There NS-398, respectively [168] . In addition, flavocoxid has been shown to downregulate both p38 and JunK [166] . Finally, flavocoxid has potent, direct antioxidant activity and prevents the oxidative generation of malondialdehyde [166, 168] . 
